China Pituitary Disease Registry (CAPASITY)

Launched by SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · Jan 14, 2021

Keywords

ClinConnect Summary

The CAPASITY trial is studying pituitary disease, which includes various conditions that affect the pituitary gland, a small but important part of the brain that helps control many bodily functions. This trial, started in 2020 in China, aims to create a better way to manage and treat these conditions using an online health information platform. By collecting and analyzing data from multiple medical centers, the researchers hope to improve how pituitary diseases are diagnosed and treated.

To participate in this trial, you need to be between 18 and 75 years old and have been diagnosed with pituitary adenomas or other pituitary diseases. If you qualify, you’ll be asked to provide your consent and follow the study's guidelines. Participants can expect to contribute to important research that may lead to better treatments for pituitary diseases while receiving care in a supportive environment. However, individuals with certain serious health issues or infections may not be eligible to join the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years old and ≤ 75 years
• • Patients diagnosed with pituitary adenomas, and other pituitary diseases
• • Pituitary adenomas resected by transsphenoidal surgery were identified by histological diagnoses.
• • Gender: males and females
• • Provide written informed consent
• • Satisfactory compliance
• Exclusion Criteria:
• • Patients with significantly reduced life expectancy (less than 2 years)
• • With Drug abuse
• • With AIDS or syphilis or infectious diseases such as viral tuberculosis in active phase at enrollment